The number of tumors in the colon was significantly reduced in the GLB and NLRP3-KO groups compared to the CTRL cohort (Figure 3D,F), suggesting that GLB treatment and NLRP3 deficiency had suppressed the development of colorectal tumors associated with colitis. The gene discussed is NLRP3; the disease is colorectal neoplasm.